Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome
Open Access
- 18 June 2012
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 26 (11), 2439-2441
- https://doi.org/10.1038/leu.2012.162
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II studyBritish Journal of Haematology, 2008
- A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1‐PDGFRA‐expressing patientsBritish Journal of Haematology, 2008
- The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective studyHaematologica, 2007
- Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemiaBlood, 2007
- FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophiliaBlood, 2004
- CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyBlood, 2003
- Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenessBlood, 2003
- Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disordersBlood, 2003
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeNew England Journal of Medicine, 2003
- Treatment of hypereosinophilic syndrome with imatinib mesilateThe Lancet, 2002